The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Workforce
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Phase 2 Results for Mavrilimumab Are In

Phase 2 Results for Mavrilimumab Are In

November 19, 2018 • By Mary Beth Nierengarten

  • Tweet
  • Email
Print-Friendly Version / Save PDF
ustas7777777 / shutterstock.com

ustas7777777 / shutterstock.com

Recent data showing sustained, long-term safety and efficacy of mavrilimumab for the treatment of rheumatoid arthritis (RA) confirm and build on prior evidence from phase 2 studies of the potential for this new agent for the treatment of RA.

You Might Also Like
  • Atacicept, Mavrilimumab Drug Updates, Trials, Safety Data
  • Certolizumab Pegol Promising for Plaque Psoriasis in Phase 3 Trial
  • The OPAL Beyond Study: Tofacitinib Phase 3 Results Positive for Treating PsA
Explore This Issue
November 2018
Also By This Author
  • Challenges Rheumatologists Will Face in 2017

Mavrilimumab is a human monoclonal antibody that blocks a proinflammatory cytokine involved in RA pathogenesis—granulocyte-macrophage colony-stimulating factor (GM-CSF)—and is the first agent targeting the receptor of this cytokine.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The study found mavrilimumab remained well tolerated with only mild or moderate adverse events and no signs of pulmonary deterioration. In addition, long-term efficacy was maintained.1

“These results support data from previous studies,” says lead author of the study, Gerd R. Burmester, MD, professor of medicine and director of the Department of Rheumatology and Clinical Immunology, Charité-University Medicine Berlin, Germany.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Unique to this study was the use of multiple pulmonary function tests to provide a longitudinal, long-term assessment of pulmonary function. A particularly important finding was that no pulmonary deterioration occurred with long-term use of mavrili­mumab. Identifying long-term effects of mavrilimumab on pulmonary function is particularly important given the potential harmful effects of blocking GM-CSF, which plays a critical role in lung homeostasis and promoting alveolar macrophage development.

A particularly important finding was that no pulmonary deterioration occurred with long-term use of mavrilimumab.

A Closer Look

Dr. Burmester

Dr. Burmester

In the study, Dr. Burmester and his colleagues pulled together data from three prior studies of mavrilimumab to assess sustained safety and efficacy for up to three years.2-4 Table 1 lists the studies.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

When combining the safety data from these studies, Burmester and colleagues found that 442 patients from these three studies received 100 mg mavrilimumab every other week with a cumulative mavrili­mumab safety exposure of 899 patient-years. Of the treatment-emergent adverse events reported, most were mild to moderate, with nasopharyngitis as the most common (n=69; 7.68 per 100 patient-years) followed by bronchitis (n=51; 5.68 per 100 patient-years). The study also found low incidences of neutropenia (0.90%; 0.54 per 100 patient-years) and serious infections (3.17%; 1.56 per 100 patient-years). There were no reports of monocytopenia.

Key: DAS28-CRP, Disease Activity Score in 28 Joints; DMARDs, disease-modifying anti-rheumatic drugs; TNF, tumor necrosis factor

(click for larger image) Table 1. Key: DAS28-CRP, Disease Activity Score in 28 Joints; DMARDs, disease-modifying anti-rheumatic drugs; TNF, tumor necrosis factor

“Importantly,” says Dr. Burmester, “pulmonary deterioration was not evident with long-term mavrilimumab treatment in addition to standard care.”

Pulmonary function and long-term pulmonary safety are listed in Table 2. The multiple pulmonary tests used to test lung function and long-term safety included serial standardized lung function testing (FEV1/FVC), assessments of dyspnea using the Borg Dyspnea Index and chest radiographs.

Pages: 1 2 3 | Single Page

Filed Under: Conditions, Drug Updates, Rheumatoid Arthritis, Safety Tagged With: Biomarkers, mavrilimumabIssue: November 2018

You Might Also Like:
  • Atacicept, Mavrilimumab Drug Updates, Trials, Safety Data
  • Certolizumab Pegol Promising for Plaque Psoriasis in Phase 3 Trial
  • The OPAL Beyond Study: Tofacitinib Phase 3 Results Positive for Treating PsA
  • FDA Considers Tocilizumab for GCA & Piclidenoson Enters Phase 3 Trial for RA, Psoriasis

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.